Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET

Company Participants

David Krempa – Chief Business Officer
Sean Brynjelsen – Chief Executive Officer
James Gruber – Chief Financial Officer

Conference Call Participants

Chase Knickerbocker – Craig-Hallum

Operator

Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following the formal remarks, we’ll open the call up for your questions. Please be advised that this call is being recorded at the company’s request.

At this time, I would like to turn it over to David Krempa, Chief Business Officer at Eton Pharmaceuticals. Please proceed.

David Krempa

Thank you, operator. Good afternoon, everyone, and welcome to Eton’s third quarter 2024 conference call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today’s call. The release is available on our website, etonpharma.com.

Joining me on our call today, we have Sean Brynjelsen, our CEO; and James Gruber, our CFO. In addition to taking live questions on today’s call, we will be answering questions that are e-mailed to us. Investors can send their questions to investorrelations@etonpharma.com.

Before we begin, I would like to remind everyone that remarks made during today’s call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company’s filings with the SEC.

Now, I will turn the call over to our CEO, Sean Brynjelsen.

Sean Brynjelsen

Thank you, David. Good afternoon, everyone, and thank you for joining us today. It’s been a busy and exciting few months for us, and I’m looking forward to talking with all of you today at such a critical moment in Eton’s history.

Throughout the last year, we have been talking about our three-pillar strategy: one, organic growth of our existing portfolio; two, advancement of internal pipeline products; and three, value-creating business development transactions to accelerate growth. I’m pleased to report that we have delivered major progress in all three of these pillars. First, our commercial organization continues to deliver attractive organic growth from our existing products, producing our 15th straight quarter of sequential product revenue growth.

Secondly, the third quarter brought a critical milestone for our important pipeline product, ET-400, which was accepted for review by the FDA and assigned a February 28 PDUFA date. And lastly, on the business development front, we announced the signing of an asset purchase agreement to acquire Increlex last month, which represented a transformational opportunity for the company.